Biological E opens Rs 300cr facility at Genome Valley

Hyderabad: City-based life sciences player Biological E Limited on Monday inaugurated its manufacturing unit spread across 29 acres at Genome Valley in Hyderabad. The plant has been set up with an investment of Rs 300 crore. “This new facility will help our existing vaccines plant enhance the production and manufacture new products which are in the pipeline,’’ managing director Mahima Datla said and added that the facility would generate around 1,000 jobs.
The company also unveiled its new Typhoid Conjugate Vaccine (TCV), an injectable single-dose vaccine to be administered to children who are 6-month old and above as well as adults. The vaccine was developed in partnership with the GSK Vaccines Institute for Global Health, based in Italy’s Siena, which first developed the asset and transferred it to Biological E in 2013.
Subsequent developmental work on TCV was done by the company, including manufacturing process optimisation and scale up, pre-clinical studies and full clinical trials in India, the company said. It will be manufactured in the company’s manufacturing facilities in Hyderabad and is expected to be commercially available within three months.
Biological E has received approval from the Central Drugs Standard Control Organisation (CDSCO) to sell vaccine in India and has also submitted the vaccine for WHO pre-qualification (PQ) and registration in other countries.
Inaugurating the unit, Telangana industries and IT minister KT Rama Rao said: “We already produce one-third of the global vaccine requirement. We would like to strengthen our capabilities further and consolidate our position as the disease prevention capital of the world.”